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puts were taken from the IPASS trial, literature and publicly available sources. A
two-year time horizon (based on the IPASS) was applied to calculate incremental
costs, progression-free life years (PFLYs) and quality adjusted life years (QALYs).
The perspective of National Health Service (NHS) in England and Wales was used.
Sensitivity analyses were performed to assess uncertainty in the results. RESULTS:
Base-case results revealed that the companion diagnostic strategy was dominant
with improvements in effects (0.095 PFLYs, 0.020 QALYs) and reduction in costs
(-£774). Small differences in QALY estimates were a consequence of using health
utility inputs from second-line advanced NSCLC setting (intravenous treatment
only). The results were sensitive to the health utilities, probability of being a re-
sponder and sensitivity, specificity and cost of the companion diagnostic.
CONCLUSIONS: This early health technology assessment suggests that introduc-
ing a companion diagnostic prior to first-line advanced NSCLC treatment has the
potential to improve effectiveness and reduce costs compared to the gefitinib for all
strategy. Further research should aim at eliciting generic utility values to better
estimate the potential health benefits of targeted therapies in this setting.
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OBJECTIVES: To assess the cost-effectiveness of sunitinib malate as a first-line treat-
ment in metastatic renal cell carcinoma (mRCC) compared with sorafenib and inter-
feron-alfa (IFN-) in the Chinese healthcare setting.METHODS:A Markov model was
developed in Microsoft Excel® to simulate disease progression and determine out-
comes over 5 years of a hypothetical cohort of 1,000 patients with mRCC receiving
first-line treatment (in 6-week cycles, 4 weeks treatment plus 2 weeks off treat-
ment) with sunitinib compared with sorafenib as well as IFN-. The model param-
eters were derived from the Pivotal Study A6181034-A3, published literatures, gov-
ernment sources as well as clinical experts’ opinions. Only direct costs were
considered in terms of drug treatment, routine follow-up, severe adverse events,
disease progression, and costs of health care resources involved in the palliative
care of terminally-ill patients. Health outcomes were measured in LYs and QALYs.
The results were expressed as ICER and ICUR. Time horizon was 5 years and the
discount rate of 5%/year was applied to costs and effectiveness. Sensitivity analyses
were also performed. RESULTS: The results indicated that in terms of total average
cost per patient over 5 years, sunitinb was less costly (¥611,054) than sorafenib
(¥613,304), and more costly than IFN-(¥150,159). Concerning health outcomes, the
estimated gains for one patient treated with sunitnib over IFN- were 0.25 LYs and
0.29 QALYs, and over sorafenib were 0.09 LYs and 0.13 QALYs. The ICER and ICUR of
sunitinib versus IFN- were ¥1,837,954 per LY gained and ¥1,585,357 per QALY
gained, respectively. CONCLUSIONS: Results suggest that sunitinib has better clin-
ical efficacy compared to sorafenib and IFN-, and is a cost-saving alternative to
sorafenib as a first-line treatment for mRCC in China. When compared with IFN,
Sutent achieved better clinical outcomes with increased cost.
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OBJECTIVES: EGFR testing and first line tyrosine kinase inhibitor (TKI) for patients
with activating mutations is an option for the treatment of advanced non-small cell
lung cancer (NSCLC). There is few data’s on the cost-effectiveness of this strategy.
The objective of this study was to determine the incremental cost-effectiveness
ratio of first-line treatment with TKI compared to recommended chemotherapy
(cisplatin pemetrexed doublet) in patients with EGFR mutation. METHODS: A
Markov model was developed. Clinical outcomes were derived from the EURTAC
phase III trial comparing TKI to chemotherapy in first-line of NSCLC. Cost data were
estimated using individual data from French randomized clinical trial or prospec-
tive cohort, whereas utility scores derived from published data’s. Costs were lim-
ited to direct costs for medications, physician visits, hospitalizations and treat-
ment of adverse events. Analysis was limited to the period between treatment
initiation of until first progression. All costs were expressed in 2010 Euro. Sensitiv-
ity analyses were performed. RESULTS: First line treatment with TKI was more
effective than recommended chemotherapy (respectively 0.730 and 0.437 QALY),
but also more expensive (respectively 29 702 € and 18 796 € per patient). The incre-
mental cost-effectiveness ratio was then estimated at 37 221 €/QALY. Sensitivity
analyses showed the robustness of the results. CONCLUSIONS: Based on these
data, first line treatment based on TKI appeared as cost effective in EFGR mutated
advanced NSCLC patients.
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OBJECTIVES: To investigate the cost-effectiveness of Gefitinib relative to the other
alternatives used for the first line treatment of EGFR mutation positive advanced
lung cancer patients, including: gemcitabine/carboplatin, paclitaxel/carboplatin,
vinolerbin/cisplatin, gemcitabine/cisplatin and pemetrexed/cisplatin, from a pro-
vider and payer perspective in Greece METHODS: A probabilistic Markov model
was constructed with four health states: treatment response, stable disease, dis-
ease progression and death. Objective response rates, hazard ratios and utility
decrements for Gefitinib relative to paclitaxel/carboplatin were obtained from a
head-to-head trial (IPASS), while meta-analysis was used to estimate correspond-
ing data for remaining comparators. Utilities were applied to estimate Quality
Adjusted Life Years (QALYs). The databases of several hospitals were analyzed to
estimate resource utilization. Unit prices were obtained from the most up to date
official resources and reflect 2011. Outcomes were bootstrapped 5,000 times to deal
with uncertainty and to construct uncertainty intervals (UI). A discounting rate of
3.5% was applied for all outcomes. RESULTS: Mean QALYs were: 1.10 (95%UI:0.89-
1.28), 1.04 (95%UI:0.87-1.19), 0.95 (95%UI:0.80-1.05), 0.91 (95%UI:0.76-1.10), 0.90
(95%UI:0.77-1.00) and 0.87 (95%UI:0.73-0.99) for gefitinib, pemetrexed/cisplatin,
gemcitabine/cisplatin, gemcitabine/carboplatin, paclitaxel/carboplatin and vi-
nolerbin/cisplatin respectively. From a provider perspective, total treatment cost
per patient was: €61,865 (95%UI:€52,848-€71,444), €72,817 (95%UI:€65,213-€80,014),
€59,270 (95%UI:€52,830-€65,530), €60,842 (95%UI:€50,113-€71,343), €58,081 (95%UI:
€53,237-€62,628) and €54,468 (95%UI:€46,874-€62,245), respectively. Hence, gefinitib
dominates all other options apart from vinolerbin/cisplatin, which is the least
costly option. The incremental cost per QALY gained with gefitinib relative to vi-
nolerbin/cisplatin, was limited to €9,662. Similar were the results from a payer
perspective. The incremental cost per QALY gained in this case was €27,369. Prob-
abilistic analysis indicated that at a 50,000 willingness to pay threshold gefitinib
was cost-effective in 90% of cases in both perspectives of analysis. CONCLUSIONS:
Gefitinib may represent a cost-effective choice, compared with alternative used in
the first line treatment of mutation positive non-small cell lung cancer patients in
Greece.
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OBJECTIVES: : To assess cost-utility of the prophylactic HPV vaccination on the
prevention of ICC in brazilian amazonic regionMETHODS: : A Markov cohort model
was developed as an analytic tool to simulate the natural history of HPV and its
progress to ICC, considering the current preventive programs. Transition probabil-
ities assumptions were based mainly on empirical data of local and national stud-
ies. The model evaluated the addition of the vaccine to 3 cervical cancer screening
scenarios (0, 3 or 10 exams throughout life). RESULTS: : The scenario of three Pap
tests resulted in satisfactory calibration (base case). The addition of HPV vaccina-
tion would reduce by 35% the incidence of ICC, in a setting of 70% vaccination
coverage. The incremental ratio of cost-effectiveness (IRCE) was R$1200 for each
year of quality-adjusted life (QALY) saved. The sensitivity analysis confirms the
robustness of this result, and duration of immunity was the parameter with greater
variation in IRCE. CONCLUSIONS: : Vaccination has a favorable profile in terms of
cost-utility, and its inclusion in the immunization schedule would result in sub-
stantial reduction in incidence and mortality of ICC in amazonic region of Brazil
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OBJECTIVES: Cost-utility evaluation comparing Dana-Farber Cancer Institute
(DFCI) and Berlin-Frankfurt-Munster (BFM) treatment strategies for childhood ALL.
METHODS: Children treated at 7 centres in Canada, Italy and the USA were eligible
for health-related quality of life (HRQL) assessment using the Health Utilities Index
Mark 3. Parents completed assessments during 4 active treatment phases and at
2-years following therapy. Mean HRQL scores were used to calculate quality-ad-
justed life years (QALYs). Costs were calculated from the perspective of the Ontario
(Canada) health care system. Patients from 2 Ontario centres were eligible for cost-
ing. Service utilization was obtained from Canadian Institute of Health Information
Discharge Abstract Database and National Ambulatory Care Reporting System re-
cords. Standard costs were used for inpatient, outpatient and physician services.
Difference in mean cost was assessed by t-test. The analytical horizon was 5 years
after diagnosis. Future costs and QALYs were discounted at 5% per year. Sensitivity
analyses used 95% confidence bounds (CB) of mean HRQL scores and discount rates
of 0% or 3%. RESULTS:A total of 1281 HRQL assessments were collected. Costs were
measured for 28 DFCI and 66 BFM patients. Based on mean HRQL scores, BFM had
0.17 (0.16 at 3% and 0.03 at 0%) more QALYs than DFCI. On lower CB for BFM and
upper CB of DFCI mean HRQL scores, BFM had 0.16 (0.16 at 3% and 0.03 at 0%) fewer
QALYs than DFCI. Mean costs for BFM ($101484) and DFCI ($98760) did not differ
significantly (p0.777). CONCLUSIONS: The cost-utility evaluation simplified to a
QALY-effectiveness analysis because of no significant difference in mean costs.
Sensitivity analysis indicates that mean QALY estimates are imprecise and overlap
between the two strategies. Therefore, BFM and DFCI are equally QALY-effective
within the range of estimation uncertainty. Future work will focus on diagnostic
sub-groups with more precise cost and QALY estimates.
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